Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.
Overview
Overview
Tirzepatide is a synthetic dual GIP / GLP-1 receptor agonist, the first member of a new class of incretin-based therapies that simultaneously activate two receptors: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). This dual mechanism distinguishes tirzepatide from semaglutide and other first-generation GLP-1 monoagonists, and produces superior weight loss and glycemic outcomes in head-to-head clinical trials.
Tirzepatide is marketed by Eli Lilly under two brand names:
- Mounjaro: Type 2 diabetes; once-weekly subcutaneous injection
- Zepbound: Chronic weight management, obstructive sleep apnea with obesity; once-weekly subcutaneous injection
Both contain the same active molecule at identical doses. The distinction is primarily for FDA indication, insurance coverage, and prescribing context.
Approval timeline:
- May 2022: Mounjaro approved for type 2 diabetes
- November 2023: Zepbound approved for chronic weight management
- December 2024: Zepbound approved for moderate-to-severe obstructive sleep apnea with obesity
- 2026 (ongoing): Cardiovascular outcomes data from SURPASS-CVOT trial published; CKD outcomes ongoing; MMO (morbidity/mortality in obesity) outcomes ongoing
Forms
Available forms & half-lives
| Form | Approximate half-life |
|---|---|
| Subcutaneous injection (Mounjaro, Zepbound) | ~5 days (~120 hours) |
What it does
Main effects
- Substantial weight loss exceeding semaglutide: SURMOUNT-1 demonstrated −20.9% at 72 weeks on 15 mg (per-protocol −22.5%) PMID: 35658024; SURMOUNT-5 head-to-head showed ~47% more weight loss than semaglutide over 72 weeks
- Superior glycemic control vs semaglutide in T2D: SURPASS-2 showed superior A1C reduction at all three tirzepatide doses PMID: 34170647
- First-in-class OSA approval based on SURMOUNT-OSA: approved for obstructive sleep apnea with obesity (December 2024)
- Dual GIP + GLP-1 receptor agonism: GIP component adds direct adipose tissue effects beyond GLP-1 monoagonism
- Cardiovascular benefit established: SURPASS-CVOT (2026) demonstrated non-inferiority to dulaglutide for MACE, with additional improvements in A1C, weight, renal function, and all-cause mortality
- ~94% reduction in T2D progression from prediabetes in SURMOUNT-1 substudy
What to watch for
Common side effects
- Gastrointestinal effects (nausea 29–43%, diarrhea 17–22%, vomiting 10–15%, constipation 6–9%, decreased appetite): dose-dependent; pattern similar to semaglutide
- Pancreatitis: documented; FDA labeling includes warning; similar risk to semaglutide
- Medullary thyroid carcinoma: boxed warning based on rodent studies; contraindicated with personal/family history of MTC or MEN 2
- Acute kidney injury: usually secondary to dehydration from GI effects
- Gallbladder disease: modestly increased risk with substantial weight loss
- Lean mass loss: approximately 20–25% of weight lost is lean mass
- Hypoglycemia in combination with insulin or sulfonylureas (low risk as monotherapy)
- Heart rate increase (modest, 2–5 bpm)
- Weight regain on discontinuation: SURMOUNT-4 demonstrated significant weight regain when tirzepatide replaced with placebo
- Compounded tirzepatide concerns: FDA declared shortage resolved late 2024, restricting compounding pharmacy availability; legal status of continuing compounded supply contested; counterfeit products documented
Key facts
Key facts worth knowing
- Tirzepatide is a 39-amino acid synthetic peptide with a structure modeled on GIP but engineered to activate both GIP and GLP-1 receptors. Its fatty diacid modification (similar to semaglutide) enables albumin binding for extended ~5-day half-life and once-weekly dosing.
- Clinical efficacy substantially exceeds semaglutide. In the head-to-head SURMOUNT-5 trial (published 2025), tirzepatide produced approximately 47% more weight loss than semaglutide over 72 weeks. In SURMOUNT-1, participants without diabetes on 15 mg weekly tirzepatide lost an average of 22.5% of body weight at 72 weeks, among the largest results from any pharmaceutical weight loss study before retatrutide. PMID: 35658024
- SURPASS-CVOT (published 2026), the first head-to-head cardiovascular outcomes trial comparing two incretin therapies, demonstrated non-inferiority to dulaglutide (a GLP-1 monoagonist with proven CV benefit from REWIND), with additional improvements in A1C, weight, renal function, and all-cause mortality.
- The dual GIP/GLP-1 mechanism produces effects on: glucose-dependent insulin secretion (both receptors), glucagon suppression (primarily GLP-1), delayed gastric emptying (primarily GLP-1), appetite regulation (both, with overlapping and distinct effects), and adipose tissue (uniquely via GIP), possibly contributing to superior weight outcomes.
- The compound has been approved for obstructive sleep apnea with obesity based on the SURMOUNT-OSA trial, the first GLP-1 class drug to receive an indication for OSA.
- WADA status is currently NOT prohibited: incretin therapies are not on the WADA Prohibited List as of current update.
- Eli Lilly's rapid expansion of the tirzepatide indication has been notable: from T2D (2022) → obesity (2023) → OSA (2024) → ongoing CV/CKD trials. The drug is increasingly being positioned as metabolic disease therapy rather than specifically diabetes or weight loss therapy.
Legal status
Legal status
FDA-approved prescription medication. Not a controlled substance.